Study of GAS for newly diagnosed advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread beyond the pancreas.
- You have not had any treatment for your metastatic cancer yet (prior chemotherapy after surgery is okay if it ended at least 6 months ago).
- Your cancer can be seen on a CT or MRI scan with lesions at least 1 cm in size.
- You are age 18 or older, and your overall health allows you to be up and about (ECOG score 0 or 1).
- Your blood counts (white cells, platelets, hemoglobin) and liver and kidney function are within certain limits.
- You can swallow pills and do not have serious gut problems that would affect absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This study tests a new treatment approach for advanced pancreatic cancer in patients who have never received chemotherapy for their advanced disease. The trial aims to evaluate whether this new strategy can help control the cancer and improve outcomes.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.